Читать книгу Canine and Feline Epilepsy - Luisa De Risio - Страница 29

In animal models of epilepsy, antagonists acting at NMDA receptors, AMPA receptors or at Group I metabotropic receptors have potent anticonvulsant actions (Meldrum and Chapman, 1999; Rogawski and Donevan, 1999; Chapman, 2000; Moldrich et al., 2003).

NMDA receptor antagonists have been successful in stopping the maintenance phase of self-sustaining status epilepticus (SE) in rats, which suggests that these compounds may have a promising role in the treatment of unrelenting seizure activity such as SE (Mazarati and Wasterlain, 1999). Studies with selective AMPA receptor antagonists have indicated that AMPA receptors are potentially promising anticonvulsant drug targets, but at present this is uncertain (Rogawski and Donevan, 1999).

In genetic mouse models, mGlu1/5 antagonists and mGlu2/3 agonists are effective against absence seizures. Thus, antagonists at Group I mGlu receptors and agonists at Groups II and III mGlu receptors are potential anti-epileptic agents, but their clinical usefulness will depend on their acute and chronic side-effects (Moldrich et al., 2003). Potential also exists for combining mGlu receptor ligands with other glutamatergic and non-glutamatergic agents to produce an enhanced anticonvulsant effect (Moldrich et al., 2003).